Foresee Pharmaceuticals

Foresee Pharmaceuticals is a purpose-driven, clinical-stage biopharma focused on improving patient quality of life through innovative drug delivery and novel therapeutics. Its core strategy is built on two pillars: a proprietary Stabilized Injectable Formulation (SIF) platform for creating long-acting injectables that enhance compliance, and a pipeline of first/best-in-class New Chemical Entities (NCEs) for severe, underserved diseases. Key achievements include advancing multiple programs into late-stage clinical trials, such as FP-045 for Fanconi Anemia and its SIF-based Leuprolide for Central Precocious Puberty, while establishing a global partnership strategy to commercialize its products worldwide.

Proprietary Stabilized Injectable Formulation (SIF) platform, comprising sub-technologies SIF-ADAGIO™, SIF-LEGATO™, SIF-DUO™, and SIF-MEZZO™, designed to create ready-to-use, long-acting injectable therapies for improved patient compliance and convenience.

In CPP, competes against established long-acting GnRH agonists; key differentiator is 6-month dosing convenience. In Fanconi Anemia, FP-045 is a potential first-in-class therapy in a sparse landscape. The SIF platform competes with other drug delivery technologies on the basis of its stability and versatility.